ABOUT US

CBmed, an Austrian funded competence center, links excellent research infrastructure, scientific expertise, medical knowledge, national and international industry partners for systematic medical biomarker research.

CBmed brings together scientific experts with leading pharmaceutical, diagnostic, medical-technology and IT industry partners. In addition, CBmed has a strong network in the area of Biobanking including the largest Biobank in Europe, Biobank Graz, and the European Biobanking network BBMRI-ERIC. CBmed research projects will identify new biomarkers, validate potential biomarkers and conduct translational biomarker research for products to be used in clinical practice.

CBmed will develop easily applicable, targeted, minimally invasive biomarkers for better diagnosis, better therapy monitoring and a more personalized treatment of patients.

OUR VISION

Our vision is to become the world’s most recognised centre for biomarker research in personalised medicine by 2030.

This will be achieved by integrating cutting-edge technologies with international and interdisciplinary expertise in the fields of cancer and cardio-metabolic health. Together with our scientific and industry partners, we will develop solutions and products for patient care and cure.

Company presentation

  • Identifying new biomarkers

  • Validating potential biomarkers

  • Conducting translational biomarker research

  • 2014

    Foundation of CBmed Ltd. in Graz.

    CBmed is a public-private-partnership biomarker research company funded by the Austrian COMET programme for excellent technologies.

  • 2015

    First Consortium Board

    and start of 25 biomarker COMET research projects in Graz and Vienna

  • 2016

    Recognition of CBmed as first Expert Centre

    of BBMRI-ERIC in May 2016

  • 2017

    60 employees working for CBmed

    Foundation of the AMBRA (advanced medical biomarker research) PhD programme by CBmed in cooperation with the Medical University of Graz.

  • 2018

    Successful completion of 25 COMET research projects

    and 13 contract research projects with over 50 international partners on 4 continents in industry and academia.

  • 2019

    New COMET funding period granted

    and successfully started with 11 focused research projects for precision medicine

  • 2020

    Start of precision oncology services

    with global players in Korea, Japan and big pharma

  • 2022

    Completion of 2nd COMET funding period

    with outstanding results for clinical translation and new products together with industry

  • 2030

    CBmed is the world’s most recognised centre for biomarker research

    in personalised medicine through combining cutting-edge technologies with international and interdisciplinary expertise

Research projects

CBmed Projects aim to develop easily applicable, targeted, minimally invasive biomarkers for better diagnosis, better therapy monitoring and a more personalized treatment of patients.

More about all projects and partner

Chief Scientific Officer » Thomas Pieber
Chief Financial Officer, Head of TQM » Robert Lobnig
Scientific Leader Area 1 Data & Technologies » Wolfgang Wadsak
Scientific Leader Area 2 Cancer » Amin El-Heliebi
Scientific Leader Area 3 Cardio-Metabolic Health » Markus Wallner
CBsolutions Director of Business Development » Lucas Pflanzl-Knizacek
Head of Core Technologies » Barbara Prietl
Head of Human Resources » Angela Jacan
Head of Finance & Controlling » Michiel Jalink 
Purchasing » Selina Kofler
Scientific Advisor Area Cancer » Armin Gerger
Scientific Advisor Area Cardio-Metabolic Health » Harald Sourij

60

Employees

300

Employees
of cooperation partners

7

Million €
annual research volume

5

Patents

456

Publications

57

PhD & Master thesis

18

National and international scientific partners

40

National and international industry partners

The COMET Center CBmed is funded within COMET – Competence Centers for Excellent Technologies by the Federal Ministry of Climate Action, Environment, Energy, Mobility, Innovation and Technology (BMK), the Federal Ministry for Digital and Economic Affairs (BMDW), Land Steiermark (Styrian Business Promotion Agency – SFG) and Land Wien (Vienna Business Agency – WAW). The COMET program is executed by the Austrian Research Promotion Agency (FFG).

CBmed GmbH Center for Biomarker Research in Medicine
Stiftingtalstrasse 5   8010 Graz   Austria   office@cbmed.at   +43 316 385 28801

PRESS CORNER     CONTACT     IMPRINT     PRIVACY

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

OKPrivacy policy
Font Resize
Contrast
Accessibility by WAH